Material Event (Form 8-K)

Item 8.01. Other Events.

On December 5, 2025, MIRA Pharmaceuticals, Inc. (the "Company") filed a prospectus supplement (the "Current Prospectus Supplement") to increase the maximum aggregate offering amount of the shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), issuable under the At The Market Offering Agreement (the "Sales Agreement") with Rodman & Renshaw LLC, dated August 12, 2024, and amended on September 24, 2024, by an additional aggregate amount of $15,241,591. The Company previously sold $7,034,658 of shares of Common Stock pursuant to the Sales Agreement under a prior prospectus supplement. A copy of the legal opinion as to the legality of the $15,241,591 of shares of Common Stock issuable under the Sales Agreement and covered by the Current Prospectus Supplement is filed as Exhibit 5.1 attached hereto.